Toward the end of 2017, Wilmington-based pharmaceutical company Incyte announced it was starting a clinical trial for a drug it hopes could be used to treat a rare blood cancer.
Delaware Public Media science reporter Katie Peikes spoke with Incyte’s Group Vice President of Oncology Targeted Therapeutics Peter Langmuir about the status of the trial and how the drug could revolutionize treatment.
